[Quantitative changes of the cytotrophoblast in underweight and normalweight newborn after risk pregnancy and antepartal therapy (author's transl)].
A histochemical-morphometric method was used to determine at the cytotrophoblast of 73 placentas, changes in the composition of the syncytium and in the Langhans' cell count in underweight and normalweight newborn with or without antepartal maternal therapy in comparison to newborn after uneventful pregnancy. The reduction of the percentage share of mature syncytium when the share of predegenerative and degenerative syncytium is increased, as weil as the increase in the average Langhans' cell count in the placentas of premature infants, hypotrophic and eutrophic infants delivered at term after risk pregnancy, compared with normal controls, is statistically significant. Significant differences in the percentage share of mature syncytium between the placentas of premature infants and hypotrophic infants delivered at term, as well as between placentas of eutrophic infants delivered at term, depending of the nature and severity of the risk, are discussed in connection with the significance of the syncytium for the processes of material transport. No correlation with the Apgar score and the occurrence of the respiratory distress syndrome of newborn, nor with the duration of the first and second stage of lavor with macroscopic placenta peculiarities, have been found. The good correlation between placenta findings and classification characteristics of newborn, and clinical aspects of the course of pregnancy, allows the possibility of diagnostic evaluation. Our results indicat also that the morphological performance must be included in the considerations explaining the success of treatment of placental insufficiency.
D005260:Female; D006801:Humans; D007230:Infant, Low Birth Weight; D007231:Infant, Newborn; D007801:Langerhans Cells; D010920:Placenta / Q000166:cytology*; D011247:Pregnancy; D012306:Risk; D014327:Trophoblasts / Q000254:growth & development*
Quantitative Veränderungen des Zottentrophoblasten bei unter- und normgewichtigen Neugeborenen nach Risikoschwangerschaft und antepartaler Therapie.